0.00Open1.60Pre Close0 Volume29 Open Interest7.00Strike Price0.00Turnover682.04%IV-0.81%PremiumDec 13, 2024Expiry Date1.67Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9160Delta0.1063Gamma5.42Leverage Ratio-0.5027Theta0.0000Rho4.96Eff Leverage0.0003Vega
Altimmune Stock Discussion
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet